NYSE · RDY
Dr. Reddy's Laboratories Ltd
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarThe next earnings date for RDY has not been announced yet.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Dec 2026 | $0.15 | $0.15 | $0.15 | 1 |
| Mar 2027 | $0.06 | $0.06 | $0.06 | 1 |
| Jun 2027 | $0.11 | $0.11 | $0.11 | 1 |
| Sep 2027 | $0.14 | $0.14 | $0.14 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · Zacks · The Motley Fool · MarketBeat- Fintel · Oct 29, 6:44 AM EDTDr. Reddy's Laboratories Limited Announces USFDA Classifies FTO-SEZ Process Unit-02 Inspection as Voluntary Action IndicatedOn October 28, 2026, Dr. Reddy's Laboratories Limited announced that the United States Food & Drug Administration has classified the inspection outcome for its FTO-SEZ Process Unit-02, Srikakulam, Andhra Pradesh, as Voluntary Action Indicated. The inspection, which was a Pre-
- Zacks · Oct 26, 10:17 AM EDTRDY Q2 Earnings & Revenues Miss Estimates as Lenalidomide Sales FallDr. Reddy's Q2 earnings and revenues miss estimates as lower lenalidomide sales weigh on results despite growth in India and emerging markets.
- The Motley Fool · Oct 25, 3:36 PM EDTDr. Reddy's Laboratories: 3 Key Takeaways for Long-Term InvestorsSemaglutide supply reloading will begin by November 2026.
- Fintel · Oct 23, 2:51 PM EDTDr. Reddy's Laboratories Limited Reports Q2 FY 2027 Financial ResultsDr. Reddy's Laboratories Limited announced its consolidated financial results for the quarter ended September 30, 2026. The company reported revenues of ₹ 86,708 Mn, representing a decline of 1.5% year-on-year and an increase of 7.4% quarter-on-quarter. Gross margin for the
- Fintel · Oct 23, 2:39 PM EDTDr. Reddy's Laboratories Limited Appoints Akhil Ravi as Head API and Services Effective November 13, 2026Dr. Reddy's Laboratories Limited announced that its Board of Directors approved the appointment of Mr. Akhil Ravi as Head API and Services and Senior Management Personnel of the Company, and his induction as a Member of the Management Council of the Company, effective November 13
- MarketBeat · Oct 23, 2:04 PM EDTDr. Reddy's Laboratories Q2 Earnings Call HighlightsTeva Pharmaceuticals Stock: Unlock Value in This Generic Drug GemDr. Reddy's Laboratories (NYSE:RDY) reported second-quarter FY2027 revenue of INR 8,671 crore, or $905 million, down 1.5% from a year earlier but up 7.4% sequentially, as lower North American lenalidomide sales offs
- The Motley Fool · Oct 23, 12:43 PM EDTDr. Reddy's (RDY) Q2 2027 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Fintel · Oct 23, 12:29 PM EDTDr. Reddy's Laboratories Limited Reports Revenues of Rs. 86,708 Million for the Quarter Ended September 30, 2026Dr. Reddy's Laboratories Limited reported revenues of Rs. 86,708 million for the three months ended September 30, 2026, representing a decrease of 2% compared to Rs. 88,051 million for the three months ended September 30, 2025. Profit for the period was Rs. 9,134 million, down fr
- RTTNews · Oct 23, 9:01 AM EDTDr. Reddy's Laboratories Profit Drops In Q2(RTTNews) – Friday, Dr. Reddy's Laboratories Limited (RDY) announced its financial results for the second quarter of fiscal 2027.
- BNK Invest · Oct 20, 4:11 PM EDTRDY Crosses Above Key Moving Average LevelIn trading on Tuesday, shares of Dr. Reddy's Laboratories Ltd. (Symbol: RDY) crossed above their 200 day moving average of $13.21, changing hands as high as $13.35 per share. Dr. Reddy's Laboratories Ltd. shares are currently trading up about 1.5% on the day. The chart below s
- Zacks · Oct 12, 3:24 PM EDTTop Stock Reports for Oracle, American Express & ProgressiveOracle, American Express and Progressive face contrasting challenges and growth drivers, from underperformance to rising expenses, premium growth and strategic investments.
- Zacks · Aug 25, 1:26 PM EDTNBIX vs. TEVA: Which Drugmaker Is the Better Investment?Neurocrine's strong Ingrezza growth, Crenessity momentum and expanding pipeline make it the stronger pick over Teva despite valuation risks.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Dr. Reddy's Laboratories Ltd from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.